Highlights Humanigen, Inc.

Equities

HGENQ

US4448632038

Market Closed - OTC Markets Other stock markets 02:58:54 2024-06-12 pm EDT			5-day change	1st Jan Change
0.0003 ^USD	+50.00%		+29,900.00%	-75.00%

May. 01	Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	CI
Apr. 12	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

19 treatment developer Humanigen files for Chapter 11 bankruptcy	Jan. 04	RE
Humanigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Traders Await -3-	23-03-31	DJ
Humanigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Humanigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B	22-07-12	CI
Humanigen, Inc. Provides Regulatory Updates on Lenzilumab	22-06-30	CI
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom	22-06-16	CI
Humanigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Humanigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Humanigen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-28	CI
Humanigen Launches Managed Access Program for Lenzilumab	22-02-09	CI
Humanigen, Cenexi Enters Collaboration for Manufacturing of Investigational COVID-19 Drug Lenzilumab	22-02-09	MT
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France	22-02-08	CI
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T	22-01-10	CI
Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved	22-01-05	CI
Humanigen, Inc. Provides Regulatory Update on lenzilumab for the Treatment of COVID-19 in the United States, United Kingdom, and the European Union	22-01-05	CI
Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study	22-01-03	CI
Humanigen Q3 Net Loss Widens Compared With Year-Ago Quarter	21-11-12	MT
Humanigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Humanigen, Inc.

Equities

HGENQ

US4448632038

Highlights

Filters